Key Developments: Omnicell Inc (OMCL.OQ)
21.57USD
1 Aug 2013
$0.47 (+2.23%)
$21.10
$21.15
$21.62
$20.94
49,066
53,165
$21.62
$12.61
Latest Key Developments (Source: Significant Developments)
Omnicell Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance-Conference Call
Omnicell Inc announced that for fiscal 2013, it expect revenue to be between $370 million and $380 million. The Company previously expected non-GAAP earnings to be between $0.97 and $1.05 per share. Because of the results in Q1, the Company now expect non-GAAP earnings to be $0.99 to $1.07 per share. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $375 million and EPS of $1.02 for fiscal 2013. Full Article
Omnicell Inc Issues Q1, FY 2013 Guidance In Line With Analysts' Estimates-Conference Call
Omnicell Inc announced that for first quarter of 2013, it expects revenue to be in the range of $86 million to $88 million and approximately $0.19 non-GAAP earnings per share (EPS). For fiscal 2013, it expects revenue to be between $370 million and $380 million and non-GAAP EPS to be between $0.97 and $1.05. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $87 million and EPS of $0.20 for first quarter of 2013; revenue of $375 million and EPS of $1.05 for fiscal 2013. Full Article
Omnicell Inc Secures Contract
Omnicell Inc announced that Sidra Medical and Research Center has selected Omnicell as the exclusive provider of automated medication management solutions throughout its facility. Omnicell's G4 platform will serve as an integral component of Sidra's planned wireless and virtually paperless nursing and pharmacy operations. Sidra's mission is to provide world-class patient care along with medical education and research. Full Article
Springhill Medical Center Selects Omnicell Inc's Omnicell Medication Automation Solutions
Omnicell Inc announced that Springhill Medical Center has selected Omnicell as its exclusive provider for medication management solutions throughout its 252-bed hospital in Mobile, AL . In addition to transitioning to Omnicell's automated medication solutions, Springhill is also using the Pandora business analytics solutions from Omnicell. Prior to installing Pandora, Springhill was utilizing a much more labor intensive method of managing their healthcare data. Full Article
Omnicell Inc Secures Contract
Omnicell Inc announced that the University of South Alabama Health System (USA), based in Mobile, Ala., selected Omnicell to be its provider of automated medication management solutions throughout USA Medical Center and USA Children's & Women's Hospital. The University of South Alabama Health System's Omnicell G4 technology investment will replace its legacy medication management system and complement the advanced technology needs of the growing health system. Full Article
Omnicell Inc Updates On FY 2012 Guidance; Issues Q2 2012 Guidance
Omnicell Inc announced that based on current projections, the Company expects fiscal 2012 revenue to be between $307-$315 million and non-GAAP diluted earnings per share (EPS) to be between $0.75-$0.81 per share. Non-GAAP diluted earnings per share excludes stock based compensation and amortization of any acquired intangible assets as well as the step-up in inventory valuation associated with the acquisition of MTS Medication Technologies and direct expenses associated with closing the acquisition, which are estimated to be between $4.0-$4.5 million, most of which is expected to be recorded in the second quarter of 2012. For the second quarter of 2012, it expects revenue to be approximately $74 million and non-GAAP diluted earnings per share to be between $0.17-$0.18. Full Article
Omnicell Inc Closes Acquisition of MTS Medication Technologies, Inc.
Omnicell Inc announced that it has completed the acquisition of MTS Medication Technologies, Inc., a global company into medication adherence packaging systems. Omnicell previously announced on May 2, 2012 that it had signed an agreement to acquire MTS Medication Technologies. MTS Medication Technologies will continue to operate under that brand, as a wholly owned subsidiary of Omnicell, immediately following the closing of the acquisition. Full Article
Omnicell Inc. Reaffirms FY 2012 Guidance-Conference Call
Omnicell Inc. announced that for fiscal 2012, it is on track with previous guidance and expect revenue excluding MTS Medication Technologies to be between $263 million and $267 million, non-GAAP earnings, excluding MTS Medication Technologies, again, to be between $0.67 and $0.72 per share, up 14% to 22%. Full Article
Omnicell Inc. Issues FY, Q1 2012 Guidance; Revenue Guidance Below Analysts' Estimates-Conference Call
Omnicell Inc. announced that for fiscal 2012, it expects revenue to be between $263 million and $267 million and non-GAAP earnings to be between $0.67 and $0.72 per share (EPS). For the first quarter of 2012, it expects revenue to be between $63 million and $64 million and non-GAAP EPS of approximate $0.13 per share. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $275 million and EPS of $0.71 for fiscal 2012 and report revenue of $65 million and EPS of $0.15 for the first quarter of 2012. Full Article
Omnicell Inc. Sees FY 2011 Revenue Guidance At High End Of Prior Range; Raises FY2011 EPS Guidance; Issues Q4 2011 Revenue Guidance Below Analysts' Estimates-Conference Call
Omnicell Inc. announced that for fiscal 2011, it expects revenue to be at the high end of its previous guidance of between $240-$245 million and expect non-GAAP earnings per share (EPS) to be $0.57-$0.58. For the fourth quarter of 2011 it expects revenue to be in the range of $62-$63 million. According to I/B/E/S estimates, analysts were expecting the Company to report revenue of $245 million and EPS of $0.56 for fiscal 2011; revenues of $64 million for the fourth quarter of 2011. Full Article

Earnings vs.
Estimates